Payment overview · 2025
General Payments
$1,425.55
67 reported records · 33 companies
Healthcare provider profile · identity verified
Usman Khan
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MOBILE, AL · NPI 1346658416
Verified facts
What the public records show
CMS Open Payments records show Usman Khan received $1,425.55 in general payments during 2025 across 67 reported records.
PFIZER INC. accounted for 9.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence, Jakafi, Nerlynx, Venclexta, Verzenio, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Calquence by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Imbruvica by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Verzenio by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYNDAMAX as an associated drug or biological on 1880 records involving 1527 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vyndamax by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xtandi by this doctor in 2024.
PUMA BIOTECHNOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NERLYNX as an associated drug or biological on 5139 records involving 3271 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nerlynx by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $129.82 | 9.1% | 7 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $106.32 | 7.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.23 | 6.3% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $78.27 | 5.5% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $75.71 | 5.3% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $70.84 | 5.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.53 | 5.0% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $67.28 | 4.7% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $63.41 | 4.5% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $52.38 | 3.7% | 2 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $50.49 | 3.5% | 2 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $48.18 | 3.4% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $44.34 | 3.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$44.09 | 3.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.03 | 2.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.45 | 2.4% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $32.67 | 2.3% | 2 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $32.13 | 2.2% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $31.26 | 2.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $30.00 | 2.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.70 | 1.8% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $22.94 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.72 | 1.6% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $22.55 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.30 | 1.3% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.04 | 1.3% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $17.25 | 1.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.19 | 1.2% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $17.12 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.85 | 1.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $14.96 | 1.1% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $13.83 | 1.0% | 1 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $11.67 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,399.85 | 66 |
| Education | $25.70 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $106.32 | 4 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $78.81 | 4 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $78.81 | 4 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $75.71 | 3 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $70.84 | 3 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $70.53 | 4 | 2025 |
Source payment records
|
|||||
| TheraSphere Y90 Glass Microspheres 10 GBq Normalized: therasphere y90 glass microspheres 10 gbq |
Device | Boston Scientific Corporation | $67.28 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $55.20 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $50.49 | 2 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $44.09 | 2 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $33.69 | 2 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $33.69 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| LYNOZYFIC Normalized: lynozyfic |
Biological | Regeneron Healthcare Solutions, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Xermelo Normalized: xermelo |
Drug | TerSera Therapeutics LLC | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| CABLIVI Normalized: cablivi |
Biological | GENZYME CORPORATION | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $11.67 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $9.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NERLYNX nerlynx |
2025 | Nerlynx | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | VYNDAMAX open payments reported associated product |
CMS Open Payments — General Payments 1880 supporting records · 1527 recipient NPIs · example record 1228795749 |
Vyndamax · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PUMA BIOTECHNOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | NERLYNX open payments reported associated product |
CMS Open Payments — General Payments 5139 supporting records · 3271 recipient NPIs · example record 1251741512 |
Nerlynx · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamoxifen Citrate | Tamoxifen Citrate | 186 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 167 | 74 |
| Anastrozole | Anastrozole | 138 | 27 |
| Letrozole | Letrozole | 125 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 38 |
| Hydroxyurea | Hydroxyurea | 70 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 25 |
| Gabapentin | Gabapentin | 66 | 24 |
| Potassium Chloride | Potassium Chloride | 57 | 25 |
| Verzenio | Abemaciclib | 52 | suppressed |
| Prednisone | Prednisone | 51 | 16 |
| Ondansetron Odt | Ondansetron | 47 | 30 |
| Acyclovir | Acyclovir | 40 | 12 |
| Revlimid | Lenalidomide | 40 | suppressed |
| Imbruvica | Ibrutinib | 35 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Xtandi | Enzalutamide | 29 | suppressed |
| Venclexta | Venetoclax | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Brukinsa | Zanubrutinib | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Calquence | Acalabrutinib Maleate | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Promacta | Eltrombopag Olamine | 17 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 16 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nerlynx | Neratinib Maleate | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 12 | suppressed |
| Tasigna | Nilotinib Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Vyndamax | Tafamidis | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,425.55 · 67 records | PFIZER INC. | ACCRUFER, AKEEGA, BALVERSA, BLENREP, BRAFTOVI, CABLIVI, CALQUENCE, CARVYKTI, DARZALEX, DATROWAY, ENJAYMO, ERLEADA, Enhertu, Epkinly, IBRANCE, IMFINZI, INGREZZA, INLYTA, INQOVI, JAKAFI, JAYPIRCA, KISQALI, LIBTAYO, LONSURF, LORBRENA, LYNOZYFIC, MONJUVI, MONOFERRIC, NERLYNX, OJJAARA, OPDUALAG, ORGOVYX, Orserdu, PADCEV, PLUVICTO, QINLOCK, REBLOZYL, ROMVIMZA, RYBREVANT, SIR-Spheres Microspheres, TAGRISSO, TALZENNA, TECVAYLI, TUKYSA, TheraSphere Y90 Glass Microspheres 10 GBq, Trodelvy, VENASEAL, VENCLEXTA, VERZENIO, Vyloy, WELIREG, XPOVIO, XTANDI, Xermelo, ZYNYZ, clonoSEQ | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error